100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Contract Awards
Purchase Order HHSN261201500364P
Award Date
9/10/15
Potential Completion Date
9/9/16
Potential Value
$32K
Overview
Contacts
Activity
1
Transactions
1
Subawards
Opportunity Stack
Similar Awards
Federal Agency
National Cancer Institute
Awardee
Gene Square Bio-Technology LTD. P2TKEBPJJ5N1
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
China
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Update #1
Update #2
QUANTIFY AND SCAN DNA SAMPLES ON CUSTOMER'S ILLUMINA OMNIEXPRESS CHIPS
Posted 9/4/15
5
1
Name
Description
Solicitation Number
FederalAgency
Type
PostedDate
Quantify and Scan DNA Samples on Customer's Illumina OmniExpress Chips
Added: Aug 17, 2015 1:13 pm Contracting Office Address:Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATESDescription:National Cancer Institute (NCI), Div. of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB), plans to procure on a sole source basis the laboratory services to quantify and scan DNA samples on Customer's Illumina OmniExpress Chips from BEIJING GENE-SQUARE BIOTECH LTD., Room 207, Tower C, Shu Guang Building, No. 5 Jing Shun Road, Chao Yang District, Beijing, China 100028.The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 621511 and the business size standard is $32.5M.Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price, type contract.The period of performance will be twelve (12) months from date of award.It has been determined there are no opportunities to acquire green products or services for this procurement.The Division of Cancer Epidemiology and Genetics (DCEG) is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The Division is the world's most comprehensive cancer epidemiology research group. Its renowned epidemiologists, geneticists, and biostatisticians conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Division's research impacts public health policy in the United States and around the world.The Occupational and Environmental Epidemiology Branch (OEEB) conducts studies in the United States and abroad to identify and evaluate environmental and workplace exposures that may be associated with cancer risk.The contribution of environmental, occupational and genetic factors to leukemia has generated a series of novel, cutting edge findings in studies of Caucasians. However, the ability to follow-up, confirm, and extend these observations has become limited by the low prevalence and limited range of several important chemical exposures and the high to complete linage disequilibrium between key candidate genetic loci in Western populations. To optimize the ability to build on and clarify these finding, it is necessary to investigate populations that differ from Caucasians in both exposure patterns and underlying genetic structure. Thus, it's valuable to scan DNA from several hospital-based case-control studies of leukemia in East Asia, including an on-going hospital-based case control studies carrying out by the NCI (Asia Lymph). The major postulated risk factors for evaluation in this study are chemical exposures (e.g. benzene), genetic susceptibility and infectious agents. This study should confirm and extend previous findings, and yield novel insights into the causes of leukemia in both Asia and the West.The Contractor shall perform the following tasks for 820 DNA samples:1. Quantify DNA samples and adjust concentration as needed2. Scan DNA samples on Illumina OmniExpress chips, to be provided by the NCI.Government Responsibilities: 820 DNA samples from studies of leukemia in China will be shipped to the Contractor. Samples will not have any personal identifiers attached. In addition, the NCI will ship to the Contractor enough Illumina OmniExpress 750K chips and reagents to scan the 820 DNA samples.Reporting Requirement and Deliverables: The Contractor shall call the NCI Contracting Officer's Representative (COR) biweekly to report the number of samples processed. The Contractor shall deliver to the NCI COR the results of the scanned DNA samples by uploading the data files to a site to be set up by the NCI.Inspection and acceptance criteria: The NCI will have fifteen (15) business days in which to review and accept these data. If no comments or request for revisions are provided within fifteen (15) business days the deliverables shall be considered acceptable.This laboratory service is provided by BEIJING GENE-SQUARE BIOTECH LTD. Gene-square is an Illumina's certified service provider, and is the highest-quality service provider in China. China has imposed restrictions on the export of DNA samples if a lab within China can conduct the similar task to the ones out of the country. Therefore, a lab in China needs to conduct scanning DNA samples collected in China. In addition, the identified lab must be able and willing to accept the chips and reagents that will be provided by the NCI to perform this work. Market research identified the proposed Vendor as the only Vendor in China that can provide this service, and is willing and able to use the NCI-provided chips and reagents (rather than using its own chips). Further, the Beijing Gene-Square Biotech laboratory has previously analyzed DNA samples from cases and controls for the NCI lung cancer and lymphoma studies carried out in China. Using the same method, the Beijing laboratory will analyze DNA samples from the NCI's study of leukemia in Eastern Asia. It is critically important that Gene-square analyze these samples so that the OEEB can use data from control patients from the lymphoma study, which were scanned by Gene-square for the previous NCI study, as the comparison group for the 820 new cases that will be scanned under this procurement. This will ensure that the new data is scientifically comparable to previous data generated by Gene-Square. If the same analysis is not used, the NCI will not be able to combine and compare the results of the two (2) studies. The performance characteristics and quality of the needed services, uniquely provided by the proposed Vendor are required for maintaining the integrity of on-going studies, and a change would be disruptive.This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 1:30PM EDT, on Aug. 27, 2015. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) tough SAM.gov. Reference: N02CP52670-76 on all correspondence.
N02CP52670-76
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
8/17/15, 1:13 PM
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
QUANTIFY AND SCAN DNA SAMPLES ON CUSTOMER'S ILLUMINA OMNIEXPRESS CHIPS
Not listed
$32.0k
9/4/15